Evidence map›Paper›PMID 33168078›Full record

ArticleActa neuropathologica communications2020

Carriership of two copies of C9orf72 hexanucleotide repeat intermediate-length alleles is a risk factor for ALS in the Finnish population.

Karri Kaivola, Samuli J Salmi, Lilja Jansson, Jyrki Launes, Laura Hokkanen, Anna-Kaisa Niemi, Kari Majamaa, Jari Lahti, Johan G Eriksson, Timo Strandberg and 2 more

Open access · goldAbstract read
In one paragraph

Article in Acta neuropathologica communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.3field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Distribution of theFrontiers in neurology · 2024
    Article
  6. Review
  7. Evidence-based consensus guidelines for ALS genetic testing and counseling.Annals of clinical and translational neurology · 2023
    Article
  8. Frontiers in genetics · 2023
    Article
  9. Response to the letter by de Boer et al. (2022).Acta neuropathologica communications · 2022
    Article
  10. Article
  11. Expanding Clinical Spectrum ofNeurology. Genetics · 2022
    Review
  12. Article
  13. Review
  14. The repeat length ofFrontiers in neurology · 2022
    Article
  15. International journal of molecular sciences · 2021
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 3 countries.

Karri KaivolaTranslational Immunology, Research Programs Unit, University of Helsinki, Helsinki, Finland. karri.kaivola@helsinki.fi.ORCID https://orcid.org/0000-0003-1218-4014
Samuli J SalmiTranslational Immunology, Research Programs Unit, University of Helsinki, Helsinki, Finland.
Lilja JanssonTranslational Immunology, Research Programs Unit, University of Helsinki, Helsinki, Finland.
Jyrki LaunesDepartment of Psychology and Logopedics, University of Helsinki, P.O. Box 21, 00014, Helsinki, Finland.ORCID https://orcid.org/0000-0002-3477-398X
Laura HokkanenDepartment of Psychology and Logopedics, University of Helsinki, P.O. Box 21, 00014, Helsinki, Finland.ORCID https://orcid.org/0000-0001-8342-9248
Anna-Kaisa NiemiResearch Unit of Clinical Neuroscience, Neurology, University of Oulu, P.O. Box 5000, 90014, Oulu, Finland.
Kari MajamaaResearch Unit of Clinical Neuroscience, Neurology, University of Oulu, P.O. Box 5000, 90014, Oulu, Finland.
Jari LahtiDepartment of Psychology and Logopedics, University of Helsinki, P.O. Box 21, 00014, Helsinki, Finland.ORCID https://orcid.org/0000-0002-4310-5297
Johan G ErikssonDepartment of Obstetrics & Gynaecology and Human Potential Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore and Singapore Institute for Clinical Sciences, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
Timo StrandbergCenter for Life Course Health Research/Geriatrics, University of Oulu, Oulu, Finland.
Hannu Laaksovirta *Translational Immunology, Research Programs Unit, University of Helsinki, Helsinki, Finland.
Pentti J Tienari *Translational Immunology, Research Programs Unit, University of Helsinki, Helsinki, Finland.
University of Helsinki · FIOulu University Hospital · FIAgency for Science, Technology and Research · SG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The hexanucleotide repeat expansion in intron 1 of the C9orf72 gene causes amyotrophic lateral sclerosis (ALS) and frontotemporal dementia. In addition to the effects of the pathogenic expansion, a role of intermediate-length alleles has been suggested in ALS, corticobasal degeneration and Parkinson's disease. Due to the rarity of intermediate-length alleles with over 20 repeats and the geographical variability in their frequency, large studies that account for population stratification are needed to elucidate their effects. To this aim, we used repeat-primed PCR and confirmatory PCR assays to determine the C9orf72 repeat allele lengths in 705 ALS patients and 3958 controls from Finland. After exclusion of expansion carriers (25.5% of the ALS patients and 0.2% of the controls), we compared the frequency of intermediate-length allele carriers of 525 ALS cases and 3950 controls using several intermediate-length allele thresholds (7-45, 17-45, 21-45, 24-45 and 24-30). The carriership of an intermediate-length allele did not associate with ALS (Fisher's test, all p ≥ 0.15) nor was there any association with survival (p ≥ 0.33), when we divided our control group into three age groups (18-65, 66-84 and 85-105 years). Carriership of two intermediate-length alleles was associated with ALS, when the longer allele was ≥ 17 repeats (p = 0.002, OR 5.32 95% CI 2.02-14.05) or ≥ 21 repeats (p = 0.00016, OR 15.21 95% CI 3.79-61.0). Our results show that intermediate-length alleles are a risk factor of ALS when present in both alleles, whereas carrying just one intermediate-length allele was not associated with ALS or survival.

Indexed as

AdolescentAdultAgedAged, 80 and overAllelesAmyotrophic Lateral SclerosisC9orf72 ProteinCase-Control StudiesDNA Repeat ExpansionFemaleFinlandHumansMaleMiddle AgedRisk FactorsSurvival RateC9orf72 ProteinC9orf72 protein, humanAgingALSC9orf72Case-control analysisIntermediate repeats

Identifiers

PMID33168078
PMCPMC7654028
OpenAlexW3101217340

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.